Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Altor BioScience Corporation
Hollywood, Florida, United Statesaltorbioscience.com ↗
- Ownership
- Private
- Employees
- ~49
- Development stage
- Other
01
Overview
Altor BioScience has developed multiple immunotherapeutic agents with its lead product Nogapendekin alfa inbakicept-pmln (IL15R agonist) receiving FDA approval on April 22, 2024. The company has completed Phase II trials for ALT-801 (p53 scTCR/IL-2 fusion) for melanoma and bladder cancer, and ALT-836 (anti-tissue factor mAb) for ALI/ARDS and solid tumors.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Cytokine-based immunotherapeuticsFusion proteinsAntibody fusion proteinsNatural killer cell therapiesSingle chain T cell receptors
- Industry
- Biotech
02
Partnerships
NantKwest Inc.
Beyond the preview
Go deeper on Altor BioScience Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Altor BioScience Corporation.